Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.
Bibliographical noteFunding Information:
Supported in part by the Kirsch Laboratory for WM, International Waldenstrom Macroglobulinemia Foundation, Leukemia and Lymphoma Society, and NIH R21 CA112904-01.